M&A - CervoMed Inc.

Form Type: 10-K

Filing Date: 2025-03-17

Corporate Action: Merger

Type: Update

Accession Number: 000143774925007829

Filing Summary: CervoMed Inc., previously known as Diffusion Pharmaceuticals Inc., completed a merger on August 16, 2023, with EIP Pharma, Inc. as part of a Merger Agreement dated March 30, 2023. This transaction designated EIP as the accounting acquirer, and all references to CervoMed's operations from this date forward reflect the business previously conducted by EIP. The merger included a reverse stock split of the common stock in a 1-for-1.5 ratio, adjusting outstanding shares from EIP into CervoMed's common stock at an exchange ratio of 0.1151. Subsequent financial results now encompass the combined operations. The report also includes detailed financial performance metrics, auditing assertions regarding internal controls, risk factors, and projections concerning future financial conditions and market strategies. CervoMed plans to continue expanding its clinical trials and participation in relevant market activities, leveraging its recent merger to enhance capital and operational capabilities moving forward.

Document Link: View Document